Price movement over the last 24 hours
Aehr Test Systems vs Nuwellis Inc — how do they compare? Aehr Test Systems trades at $67.2 (market cap $2.11B), while Nuwellis Inc trades at $2.81 (market cap $1.15M). The key difference: Aehr Test Systems is far larger — about 1834.8× Nuwellis Inc's market cap, and Aehr Test Systems is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| AEHR | NUWE | |
|---|---|---|
Market Cap | $2.11B | $1.15M |
Sector | Technology | Technology |
52-Week High | $116.58 | $558.26 |
52-Week Low | $13.29 | $3.05 |
Enterprise Value | $2.08B | -$662.47K |
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
NUWE trades at $3.29, up 4.44% today, but faces a bearish technical outlook with moving averages signaling a downtrend. The company reported a net loss of $17.52 million in 2025, with a negative net income margin of -217.22%, though it beat earnings expectations in two of the last three quarters. Recent news highlights expansion efforts, including new CEO Mike McCormick outlining strategic priorities and a $6 million public offering closed in June 2026 to support growth.
The outlook remains challenging due to persistent losses and high cash burn, but low valuation ratios like a P/E of 0.64 and P/B of 0.45 may attract value investors. Key risks include the need to achieve profitability and competitive pressures in the medical technology sector. Analyst sentiment is mixed with a 50% buy rating, suggesting cautious optimism amid fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →